• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.49 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 139
Open 14.49
Bid (Size) 14.20 (8,000)
Ask (Size) 14.65 (100)
Prev. Close 14.49
Today's Range 14.49 - 14.49
52wk Range 12.26 - 16.17
Shares Outstanding 166,301,231
Dividend Yield 0.63%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
February 20, 2026
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test ↗
February 03, 2026
Via Chartmill

Performance

YTD
+4.5%
+4.5%
1 Month
+5.9%
+5.9%
3 Month
+6.1%
+6.1%
6 Month
+0.2%
+0.2%
1 Year
+7.4%
+7.4%

More News

Read More
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
January 14, 2026
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Passes Peter Lynch's GARP Investment Filter ↗
January 10, 2026
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens ↗
December 18, 2025
Via Chartmill
News headline image
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
December 02, 2025
From Aurigene Oncology Limited
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
November 26, 2025
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
November 04, 2025
Via Chartmill
News headline image
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
October 22, 2025
From Aurigene Oncology Limited
Via Business Wire
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗
October 14, 2025
Via Chartmill
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
October 09, 2025
Via Benzinga
Topics Government World Trade
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Fits the Peter Lynch GARP Strategy ↗
September 23, 2025
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment ↗
September 02, 2025
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy ↗
August 12, 2025
Via Chartmill
News headline image
Dr. Reddy’s Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year
August 04, 2025
Via AB Newswire
Topics Earnings
News headline image
Dr. Reddy’s Q1FY26 Financial Results
July 23, 2025
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching ↗
July 22, 2025
Via Chartmill
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
July 17, 2025
Via AB Newswire
Topics Death
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗
June 30, 2025
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
June 09, 2025
Via Chartmill
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
June 05, 2025
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
June 05, 2025
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
June 05, 2025
From Alvotech
Via GlobeNewswire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
May 16, 2025
Via Chartmill
News headline image
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
May 09, 2025
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire

Frequently Asked Questions

Is Dr. Reddy's Laboratories Ltd Common Stock publicly traded?
Yes, Dr. Reddy's Laboratories Ltd Common Stock is publicly traded.
What exchange does Dr. Reddy's Laboratories Ltd Common Stock trade on?
Dr. Reddy's Laboratories Ltd Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock?
The ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock is RDY on the New York Stock Exchange
What is the current price of Dr. Reddy's Laboratories Ltd Common Stock?
The current price of Dr. Reddy's Laboratories Ltd Common Stock is 14.49
When was Dr. Reddy's Laboratories Ltd Common Stock last traded?
The last trade of Dr. Reddy's Laboratories Ltd Common Stock was at 02/20/26 07:00 PM ET
What is the market capitalization of Dr. Reddy's Laboratories Ltd Common Stock?
The market capitalization of Dr. Reddy's Laboratories Ltd Common Stock is 2.41B
How many shares of Dr. Reddy's Laboratories Ltd Common Stock are outstanding?
Dr. Reddy's Laboratories Ltd Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap